Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$33.37 +3.4%	$34.35	$21.62 ▼ $39.54	$6.13B	1.15	2.44 million shs	2.62 million shs
LNTH Lantheus	$75.52 +1.8%	$92.56	$73.11 ▼ $126.89	$5.22B	0.23	990,521 shs	912,040 shs
RVMD Revolution Medicines	$39.08 +3.6%	$37.53	$29.17 ▼ $62.40	$7.28B	1.11	1.51 million shs	1.81 million shs
SDGR Schrödinger	$21.44 -0.4%	$22.70	$16.60 ▼ $28.47	$1.57B	1.84	868,527 shs	759,424 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-2.54%	-1.77%	-10.11%	-5.96%	+15.96%
LNTH Lantheus	-2.09%	-1.26%	-27.77%	-18.92%	-6.62%
RVMD Revolution Medicines	+2.06%	-2.61%	-9.02%	-3.45%	-0.45%
SDGR Schrödinger	+0.09%	+4.92%	-16.43%	-3.28%	-2.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.5253 of 5 stars	4.5	1.0	3.9	3.2	3.3	0.6
LNTH Lantheus	4.3347 of 5 stars	3.5	1.0	4.2	2.7	2.5	1.9
RVMD Revolution Medicines	4.2845 of 5 stars	4.5	0.0	4.7	3.6	2.5	0.0
SDGR Schrödinger	2.2406 of 5 stars	3.5	1.0	0.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.92	Moderate Buy	$57.09	71.08% Upside
LNTH Lantheus	3.00	Buy	$132.67	75.67% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	71.66% Upside
SDGR Schrödinger	3.00	Buy	$32.80	52.99% Upside

Current Analyst Ratings Breakdown

Latest SDGR, RVMD, LNTH, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/8/2025	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$127.00 ➝ $117.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00
5/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
4/30/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$46.00 ➝ $63.00
4/30/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$52.00 ➝ $55.00
4/30/2025	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $72.00
4/28/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00 ➝ $67.00
4/16/2025	SDGR Schrödinger	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $32.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$127.42M	49.73	N/A	N/A	($7.71) per share	-4.33
LNTH Lantheus	$1.54B	3.40	$6.30 per share	11.98	$11.91 per share	6.34
RVMD Revolution Medicines	$742K	9,810.45	N/A	N/A	$11.09 per share	3.52
SDGR Schrödinger	$230.49M	6.83	$0.57 per share	37.42	$7.60 per share	2.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-241.44%	N/A	-75.69%	8/7/2025 (Estimated)
LNTH Lantheus	$326.66M	$3.52	12.57	11.97	N/A	28.57%	44.29%	23.52%	7/30/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)
SDGR Schrödinger	$40.72M	-$2.63	N/A	N/A	N/A	-91.84%	-35.77%	-24.51%	7/30/2025 (Estimated)

Latest SDGR, RVMD, LNTH, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/7/2025	Q1 2025	SDGR Schrödinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SDGR Schrödinger	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.67	4.67
LNTH Lantheus	N/A	1.65	1.56
RVMD Revolution Medicines	N/A	14.24	14.24
SDGR Schrödinger	N/A	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
LNTH Lantheus	99.06%
RVMD Revolution Medicines	94.34%
SDGR Schrödinger	79.05%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
LNTH Lantheus	2.00%
RVMD Revolution Medicines	8.20%
SDGR Schrödinger	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	143.29 million	Optionable
LNTH Lantheus	700	69.19 million	68.48 million	Optionable
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable
SDGR Schrödinger	790	73.38 million	66.59 million	Optionable

SDGR, RVMD, LNTH, and BBIO Headlines

Recent News About These Companies

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29 at 9:51 PM | finance.yahoo.com

SchrÃ¶dinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29 at 6:03 PM | businesswire.com

Schrdinger, Inc. (SDGR) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today

May 29 at 10:20 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29 at 10:00 AM | accessnewswire.com

Ongoing Schrdinger, Inc. (SDGR) Investigation: Protect Your Rights - Contact Levi & Korsinsky

May 28 at 2:15 PM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

May 28 at 10:00 AM | accessnewswire.com

Integrated Advisors Network LLC Sells 17,547 Shares of Schrödinger, Inc. (NASDAQ:SDGR)

May 28 at 5:52 AM | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $31.25 Million Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR)

May 28 at 4:48 AM | marketbeat.com

BNP Paribas Financial Markets Makes New Investment in Schrödinger, Inc. (NASDAQ:SDGR)

May 28 at 3:16 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SchrÃ¶dinger, Inc. - SDGR

May 27 at 12:00 PM | accessnewswire.com

RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?

May 27 at 11:01 AM | zacks.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 27 at 10:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 26 at 10:00 AM | accessnewswire.com

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 25, 2025 | accessnewswire.com

Millennium Management LLC Raises Position in Schrödinger, Inc. (NASDAQ:SDGR)

May 25, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR

May 24, 2025 | accessnewswire.com

Captrust Financial Advisors Takes $240,000 Position in Schrödinger, Inc. (NASDAQ:SDGR)

May 24, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 23, 2025 | accessnewswire.com

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 23, 2025 | businesswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025 | accessnewswire.com

Schrödinger to Present at Jefferies Global Healthcare Conference

May 22, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
By Sam Quirke | May 14, 2025
View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

SDGR, RVMD, LNTH, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$33.37 +1.11 (+3.44%)

Closing price 04:00 PM Eastern

Extended Trading

$33.31 -0.06 (-0.18%)

As of 07:32 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Lantheus NASDAQ:LNTH

$75.52 +1.34 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$76.00 +0.48 (+0.64%)

As of 07:15 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Revolution Medicines NASDAQ:RVMD

$39.08 +1.35 (+3.58%)

Closing price 04:00 PM Eastern

Extended Trading

$39.52 +0.44 (+1.14%)

As of 06:59 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Schrödinger NASDAQ:SDGR

$21.44 -0.08 (-0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$21.30 -0.14 (-0.67%)

As of 07:59 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time